Cabio Biotech Price To Sales vs. Profit Margin

688089 Stock   18.09  0.19  1.04%   
Considering the key profitability indicators obtained from Cabio Biotech's historical financial statements, Cabio Biotech Wuhan may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in February. Profitability indicators assess Cabio Biotech's ability to earn profits and add value for shareholders.
For Cabio Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cabio Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cabio Biotech Wuhan utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cabio Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cabio Biotech Wuhan over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Cabio Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cabio Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cabio Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Cabio Biotech Wuhan Profit Margin vs. Price To Sales Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Cabio Biotech's current stock value. Our valuation model uses many indicators to compare Cabio Biotech value to that of its competitors to determine the firm's financial worth.
Cabio Biotech Wuhan is number one stock in price to sales category among its peers. It also is number one stock in profit margin category among its peers fabricating about  0.04  of Profit Margin per Price To Sales. The ratio of Price To Sales to Profit Margin for Cabio Biotech Wuhan is roughly  26.62 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cabio Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cabio Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Cabio Profit Margin vs. Price To Sales

Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Cabio Biotech

P/S

 = 

MV Per Share

Revenue Per Share

 = 
6.04 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

Cabio Biotech

Profit Margin

 = 

Net Income

Revenue

X

100

 = 
0.23 %
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.

Cabio Profit Margin Comparison

Cabio Biotech is currently under evaluation in profit margin category among its peers.

Cabio Biotech Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Cabio Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cabio Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Cabio Biotech's change in net profit over the period of time. It can combine multiple indicators of Cabio Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Net Interest Income1.5 M1.7 M
Operating Income105.8 M96.8 M
Net Income From Continuing Ops99.3 M102.3 M
Income Before Tax115 M120.1 M
Net Income105.1 M102.1 M
Interest Income2.4 M3.2 M
Net Income Applicable To Common Shares57.9 M88.3 M
Income Tax Expense14 M15.8 M
Change To Netincome52.5 M55.1 M

Cabio Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Cabio Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cabio Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cabio Biotech's important profitability drivers and their relationship over time.

Use Cabio Biotech in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cabio Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cabio Biotech will appreciate offsetting losses from the drop in the long position's value.

Cabio Biotech Pair Trading

Cabio Biotech Wuhan Pair Trading Analysis

The ability to find closely correlated positions to Cabio Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cabio Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cabio Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cabio Biotech Wuhan to buy it.
The correlation of Cabio Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cabio Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cabio Biotech Wuhan moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cabio Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Cabio Biotech position

In addition to having Cabio Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Biotech Thematic Idea Now

Biotech
Biotech Theme
Companies specialized in biotechnology production and delivery of pharmaceuticals services. The Biotech theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Biotech Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Cabio Stock

To fully project Cabio Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cabio Biotech Wuhan at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cabio Biotech's income statement, its balance sheet, and the statement of cash flows.
Potential Cabio Biotech investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Cabio Biotech investors may work on each financial statement separately, they are all related. The changes in Cabio Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cabio Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.